~~<i id='340AFDEB30'><strike id='340AFDEB30'><tt id='340AFDEB30'><pre id='340AFDEB30'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

author：leisure time 2025-09-29 22:52:44 - browse：54737

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： As AI regulations shape up, health tech startups beg for clarity

focus

leisure time

entertainment

knowledge

focus

explore

1:30InthisMarch4,2018,filephoto,aBoeing737jetliner,belongingtoDeltaAirlines,isshownonthetarmacMcCarr

WSS

When a patient nears the end, a feared therapy can comfort

Dementia risk linked to living in disadvantaged areas: Study

Weight loss drugs aren’t covered by Obamacare. That may change

Delta passengers in Vegas fall sick while waiting on flight in triple

Sanders wants to replace patents with prizes for drug inventions

As AI regulations shape up, health tech startups beg for clarity

Wikipedia

Wikipedia

focus

Bright Health sells Medicare Advantage business to Molina

How a Boston hospital is priming medical residents to use GPT

Moonlake's readout produced a cash windfall. Risks remain

New study raises questions about niacin and heart health

Continuity nursing helped my family in our darkest PICU moments

Judge denies Trump's request for new trial in E. Jean Carroll case

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Abridge raises $150m as clinical notes automation market heats up

As demand for Covid shots wanes, Moderna seeks its next success

Hormonal contraceptives don’t actually treat endometriosis

leisure time

Extensive review finds private equity owners jack up cost of care

Judge denies Trump's request for new trial in E. Jean Carroll case

Obamacare plans could cover weight loss drugs

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

The stock market has soared this year, but will it last? Experts weigh in

Researchers tackle phage therapy hurdles for wider adoption

entertainment

knowledge

focus

explore